SOC in Europe (inclusive of Russia), is favipiravi

SOC in Europe (inclusive of Russia), is favipiravir. SOC in US is remdesivir. Innovation Pharmaceuticals and the CRO would never allow a participating hospital to alter the drug combination specific to the IV infusion concurrent to the treatment window. To deviate in any way places the data collected at jeopardy to be disqualified and puts the clinical trial and 3 decades of Brilacidin research and development at risk. (I am not being hyperbolic when stating this fact.)

Regardless of whether a selected and monitored clinical site is administering Brilacidin in combo with remdesivir or favipiravir; the combination of drugs, the "recipe" of that combo, the dosing schedule, monitoring and data collection must be precise and uniform across all testing sites.